Omar Mian, MD, PhD
Associate Staff
Location: Cleveland Clinic Main Campus
Research
The Mian Lab is exploring the genetic and epigenetic mechanisms underlying lethal cancers of the genitourinary tract with the goal of translating discovery into novel therapies. Our approach couples translational research to clinical investigation in GU malignancies at Cleveland Clinic's Lerner Research Institute. We are developing powerful tools for identifying predictive and prognostic biomarkers as well as for therapeutic target discovery.
Our mission is to reduce the burden of prostate and bladder cancer through fundamental discovery and to improve the lives of cancer patients.
Biography
Dr. Mian is a radiation oncologist and physician scientist at Cleveland Clinic's Lerner Research Institute. He has a appointments in Radiation Oncology, Lerner Research Institute, Cleveland Clinic Lerner College of Medicine and is an Assistant Professor of Medicine at Case Western Reserve University. He is a member of the Genitourinary Malignancies Research Program of the Case Comprehensive Cancer Center.
Education & Professional Highlights
Appointed
2016
Residency - Johns Hopkins Hospital
Radiation Oncology
Baltimore, MD USA
2016
Internship - Virginia Commonwealth University
Internal Medicine
Richmond, VA USA
2012
Medical Education - Virginia Commonwealth University Medical College
Richmond, VA USA
2011
Graduate School - Johns Hopkins University
Baltimore, MD USA
2001
Undergraduate - James Madison University
Harrisonburg, VA USA
1998
- 2014 ASCO/AACR Methods in Clinical Cancer Research Workshop, Vail, CO
- 2015 AACR Molecular Biology in Clinical Oncology Workshop, Aspen, CO
- 2014-2015 Research Fellow, Radiation Oncology, Johns Hopkins University
- 2014-2015 Vice Chair, Housestaff Council, Johns Hopkins Hospital
- 2016-2017 Clinical, Translational and Basic Science Advisory Subcommittee Member, ASTRO
- 2016-2021 Promoting Science through Education Subcommittee Member, ASTRO
- 2017-Present Radiation and Cancer Biology Course Director, Cleveland Clinic
- 2020-Present NCCN Panel Member
- Radiology - Radiation Oncology
- 2007 Alpha Omega Alpha Honor Medical Society
- 2007 VCU Research Retreat, 1st Place Poster
- 2007 Phi Kappa Phi Honor Society
- 2008 Golden Key Honor Society
- 2008 C.C. Clayton Outstanding Student Award, Molecular Biology and Genetics Program
- 2008 AMA Seed Grant, American Medical Association
- 2008 Massey Cancer Center Symposium, Excellence in Cancer Research, 1st Place Award
- 2009 American College of Physicians, VA Associates Meeting, 1st Place Poster
- 2009 Phi Kappa Phi Love of Learning Award
- 2014 Brachytherapy Next Meeting Travel Award
- 2015 1st place, Clinical Translation Research, SKCCC Fellow’s Research Retreat
- 2016 RSNA Roentgen Resident/Fellow Research Award
- 2019 CCF Radiation Oncology Educator of the Year
- 2021 National Comprehensive Cancer Network (NCCN) Young Investigator Award
- 2021 Society of Basic Urologic Research (SBUR) Young Investigator Award
- 2021 American Cancer Society Research Scholar Award
- 2013 American Brachytherapy Society (ABS)
- 2012 American Society for Radiation Oncology (ASTRO)
- 2012 American Society of Clinical Oncology (ASCO)
- 2012 American Board of Radiology (ABR)
- 2009 American Association for Cancer Research (AACR)
Research
We are exploring the genetic and epigenetic mechanisms underlying lethal cancers of the genitourinary tract with the goal of translating discovery in to novel therapies. Our approach couples translational research to clinical investigation in GU malignancies at Cleveland Clinic's Lerner Research Institute. We are developing powerful tools for identifying predictive and prognostic biomarkers as well as for therapeutic target discovery. The mission of our lab is to reduce the burden of prostate and bladder cancer through fundamental discovery and to improve the lives of cancer patients.
Our Team
Selected Publications
View publications for Omar Mian, MD, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
- Molecular Characterization of Neuroendocrine-like Bladder Cancer
Batista da Costa J, et al. Clin Cancer Res 2019. Among authors: Mian OY. PMID 30952638
- Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target
Koshkin VS, et al. Clin Cancer Res 2019. Among authors: Mian OY. PMID 30327311 Free PMC article.
- The ASTRO Research Portfolio: Where Do We Go From Here
Yu JB, et al. Int J Radiat Oncol Biol Phys 2019. Among authors: Mian OY. PMID 30647008
- Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response
Vargas R, et al. NPJ Precis Oncol 2018. Among authors: Mian OY. PMID 30202792 Free PMC article.
- Computed tomography imaging assessment of postexternal beam radiation changes of the liver
Lock M, et al. Future Oncol 2016 - Review. Among authors: Mian OY. PMID 27576360 Free PMC article.
- The landscape of early carcinogenesis revealed through the lens of integrative genomics, epigenomics, and transcriptomics
Balyimez A, et al. J Thorac Dis 2019. Among authors: Mian OY. PMID 31372248 Free PMC article.
- Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings
Purysko AS, et al. Eur Radiol 2019. Among authors: Mian OY. PMID 30847589 Free PMC article.
- Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy
Cheng Z, et al. Adv Radiat Oncol 2018. Among authors: Mian OY. PMID 30370361 Free PMC article.
- Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy
Tom MC, et al. J Urol 2019. Among authors: Mian OY. PMID 31059665
- Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy
Grivas P, et al. Urol Oncol 2019. Among authors: Mian OY. PMID 31812633
- The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin
Mian OY, et al. Transl Cancer Res 2017. PMID 30873354 Free PMC article.
- Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer
Ericson KJ, et al. Clin Adv Hematol Oncol 2019. Among authors: Mian OY. PMID 31851158
- Prevalence of Substance Use in Patients With Cancer Receiving Radiation Therapy
Choflet A, et al. Clin J Oncol Nurs 2016. Among authors: Mian OY. PMID 27441512
- Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry
Lee J, et al. Radiother Oncol 2017. Among authors: Mian OY. PMID 28647400 Free PMC article.
- Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio
Yu JB, et al. Int J Radiat Oncol Biol Phys 2019. Among authors: Mian OY. PMID 30647006
- GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress
Mian OY, et al. Prostate 2016. PMID 26447830 Free PMC article.
- Timely stereotactic body radiotherapy (SBRT) for spine metastases using a rapidly deployable automated planning algorithm
Mian OY, et al. Springerplus 2016. PMID 27563532 Free PMC article.
- Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable
Tendulkar RD and Mian OY. Int J Radiat Oncol Biol Phys 2020. PMID 31928637
- Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer
Peng LC, et al. Urology 2020. Among authors: Mian OY. PMID 31454660
- Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy
Tom MC, et al. Brachytherapy 2020. Among authors: Mian OY. PMID 31813740
Patents
| US Patent | Patent Title | Issue Date | First-Named Inventor |
|---|---|---|---|
| 7998682 | Method for assessing atherosclerosis by measuring expression of FOS or DUSP1 in monocytes | 08/16/2011 |
Careers
Postdoctoral Fellow
A Postdoctoral fellow position is available immediately in the Mian Laboratory, in the Department of Translational Hematology and Oncology Research (THOR) at the Cleveland Clinic’s Lerner Research Institute in Cleveland, OH.
A fully funded position awaits a fellow looking to pursue a dynamic career in translational biomedical research! Our lab at the Cleveland Clinic studies epigenetic, metabolic, and endocrine determinants of response to DNA damage in a variety of cancers. The work involves characterization of innovative preclinical models using genome editing and molecular analysis methods. Clinical samples are readily available for validation studies. The position offers excellent opportunities for publication, career development and advancement. Candidates will join a stimulating academic environment within the Genitourinary Malignancies Research Center of the Lerner Research Institute.
Highly motivated individuals with a strong background and interest in translational cancer research are encouraged to apply. Applicants must be recent Ph.D. or M.D./Ph.D. graduates in cell biology, molecular biology, cancer biology, molecular genetics, developmental biology or related fields. Prior experience in culture of human primary and cancer cell lines, molecular biology, as well as a track record of peer-reviewed publications is required. Individuals with additional experience in genome editing, mouse work or bioinformatics, are strongly encouraged to apply.
Interested applicants should send a CV, a cover letter/statement that describes career goals, and 3 references to Dr. Omar Mian ([email protected]).
Research News
Precision cancer medicine is the goal of a new multidisciplinary study, led by Dr. Tim Chan, examining radiation therapy combined with targeted therapy
Drs. Mian, Gupta and Hwang—a multi-disciplinary team of researchers and clinicians—will look for ways to optimize immune checkpoint inhibitor therapy, including testing novel combinatory treatments and identifying predictive biomarkers of treatment response.